Insights - Disparate results from two gene therapy developers are worth a mention in this week’s biotech recap. Avalanche Biotechnologies (AAVL) blew up spectacularly this Monday with … Continue Reading
Read nowResearch - Synergy Pharmaceuticals (SGYP) reported positive data from the first of two phase 3 trials for its constipation drug plecanatide on Wednesday.
Read nowResearch - Shares of Sage Therapeutics (SAGE) climbed higher on Tuesday with the first glimpse at SAGE-547’s potential in post-partum depression. And with it went Marinus Pharmaceuticals … Continue Reading
Read nowResearch - Following meetings with the U.S. FDA and Europe’s EMA, bluebird bio (BLUE) has clarity on the regulatory path for LentiGlobin BB305 in beta-thalassemia major. For … Continue Reading
PremiumResearch - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read nowRecap - No one has the exact answer, but Mr. King’s post-JP Morgan musings from earlier this year seem relevant yet again. As of Friday’s close, the S&P 500 is actually down year-to-date, while the biotechnology sector is up an impressive 14%, as measured by the IBB. The two have clearly diverged, and it almost seems that investors are fleeing to biotechnology for safety. That’s quite a departure from years past.
Read nowResearch - Synergy Pharmaceuticals (SGYP) will shortly report phase 3 data from two large trials of lead candidate plecanatide in Chronic Constipation.
Premium
